In a multicenter , randomized , open-label phase III study , patients 65 years with newly diagnosed AML received decitabine 20 mg/m ( 2 ) once daily for 5 days every 4 weeks ( n = 242 ) or treatment choice ( supportive care or cytarabine 20 mg/m ( 2 ) once daily for 10 days every 4 weeks ; n = 243 ) .